Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Other companies are also developing amylin-targeting drugs. Novo Nordisk’s amycretin targets both amylin and GLP-1. Viking Therapeutics, whose pipeline includes both injectable and oral agonists ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

Likewise, the injected Zepbound® resulted in 22 gastrointestinal ("GI")-related adverse events, whereas the oral ... peptide-1 / glucose-dependent insulinotropic (GLP-1/GIP) drugs.

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain ...

Oral delivery of drugs requires far higher quantities of ... its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm, oral DehydraTECH-tirzepatide will be ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria ...